Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Macroglobulinemia of Waldenstrom
- Determine the safety and possible effectiveness of antineoplastons A10 and AS2-1 in
patients with recurrent or refractory Waldenstrom's macroglobulinemia.
- Describe response, tolerance to, and side effects of this regimen in these patients.
OUTLINE: This is an open-label study.
Patients receive gradually escalating doses of antineoplastons A10 and AS2-1 by intravenous
injection 6 times daily until the maximum tolerated dose is reached.
Treatment continues for at least 3 months in the absence of toxicity or disease progression.
Patients achieving complete response (CR) continue treatment for an additional 8 months
after reaching CR.
Tumors are measured every 2 months the first year and every 3 months the second year.
PROJECTED ACCRUAL: Approximately 20-40 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
United States: Federal Government
|Burzynski Clinic||Houston, Texas 77055-6330|